ArticlePharmaceutics2020
Systemically Delivered Magnetic Hyperthermia for Prostate Cancer Treatment.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Magnetic Hyperthermia via ZnPharmaceutics · 2026Article
- In Vivo Fluorescent Melanoma Model: Electroporation Plus Magnetic Hyperthermia Significatively Reduces Tumor Size, Preliminary Results.Pharmaceutics · 2026Article
- Biomaterials Empowering in New Era of Women's Healthcare System.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Radio-magnetic dual-functional microspheres for magnetic hyperthermia therapy combined with radioembolization of hepatocellular carcinoma.Materials today. Bio · 2025Article
- Nanoparticle-based drug delivery systems in urologic oncology: From targeted therapy to precision theranostics.Materials today. Bio · 2025Review
- Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery.Bioactive materials · 2025Review
- Iron oxide based magnetic nanoparticles for hyperthermia, MRI and drug delivery applications: a review.RSC advances · 2025Review
- Optimized Zn substituted CoFeScientific reports · 2025Article
- Precision-Engineered Cobalt-doped Iron Oxide Nanoparticles: From Octahedron Seeds to Cubical Bipyramids for Enhanced Magnetic Hyperthermia.Advanced functional materials · 2025Article
- Preclinical evaluation of uPAR-ICG-FVIOs for dual-mode imaging and magnetic hyperthermia therapy in pancreatic cancer.Frontiers in pharmacology · 2025Article
- Synergistic Strategies in Prostate Cancer Therapy: Electrochemotherapy and Electromagnetic Hyperthermia.Pharmaceutics · 2024Article
- Breast Cancer Treatment Using the Magneto-Hyperthermia Technique Associated with Omega-3 Polyunsaturated Fatty Acids' Supplementation and Physical Training.Pharmaceutics · 2024Article
- Nanoparticle-Mediated Hyperthermia and Cytotoxicity Mechanisms in Cancer.International journal of molecular sciences · 2023Review
- A Survey of the Thermal Analysis of Implanted Antennas for Wireless Biomedical Devices.Micromachines · 2023Review
- Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity.Pharmaceutics · 2023Review
- Electrospun Magnetic Nanofiber Mats for Magnetic Hyperthermia in Cancer Treatment Applications-Technology, Mechanism, and Materials.Polymers · 2023Review
- A Photoacoustic Contrast Nanoagent with a Distinct Spectral Signature for Ovarian Cancer Management.Advanced healthcare materials · 2023Article
- Novel Nanoparticle-Based Treatment and Imaging Modalities.Pharmaceutics · 2023Article
- Nanotherapeutic Approach to Delivery of Chemo- and Gene Therapy for Organ-Confined and Advanced Castration-Resistant Prostate Cancer.Critical reviews in therapeutic drug carrier systems · 2023Article
- Current applications of nanomaterials in urinary system tumors.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Herein, we report a novel therapy for prostate cancer based on systemically delivered magnetic hyperthermia. Conventional magnetic hyperthermia is a form of thermal therapy where magnetic nanoparticles delivered to cancer sites via intratumoral administration produce heat in the presence of an alternating magnetic field (AMF). To employ this therapy for prostate cancer tumors that are challenging to inject intratumorally, we designed novel nanoclusters with enhanced heating efficiency that reach prostate cancer tumors after systemic administration and generate desirable intratumoral temperatures upon exposure to an AMF. Our nanoclusters are based on hydrophobic iron oxide nanoparticles doped with zinc and manganese. To overcome the challenges associated with the poor water solubility of the synthesized nanoparticles, the solvent evaporation approach was employed to encapsulate and cluster them within the hydrophobic core of PEG-PCL (methoxy poly(ethylene glycol)-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.